Elicio Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Elicio is a clinical-stage biotechnology company developing cancer immunotherapies using its Amphiphile platform. Its lead program, ELI-002, is in clinical trials. The June 1, 2023 merger with Angion was accounted for as a reverse recapitalization, with Former Elicio as the accounting acquirer. Thus, 2023 results include Angion from June 2 onward, while prior-period results are Former Elicio standalone and are not fully comparable.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Product revenue | No product sales; the company has no products approved for sale. | |||
| Research and development expense | $7.3 million | $4.6 million | $17.7 million | $13.8 million |
| General and administrative expense | $3.5 million | $1.2 million | $8.7 million | $4.0 million |
| Total operating expenses | $10.8 million | $5.8 million | $26.4 million | $17.8 million |
| Net loss | $10.7 million | $7.2 million | $26.2 million | $21.6 million |
| Net loss per share | $1.27 | $22.67 | $3.19 | $68.52 |
| Cash used in operating activities | Not separately reported for the quarter | $22.8 million | $14.9 million |
Margins are not meaningful given the absence of product revenue. At September 30, 2023, cash and cash equivalents were $14.8 million and restricted cash was $2.4 million. Current assets were $19.9 million and current liabilities $11.5 million. Total assets were $31.0 million; total liabilities were $17.7 million. No interest-bearing debt was reported at quarter-end; operating lease liabilities totaled $7.2 million.
Changes and notable items
- Q3 R&D expense rose 58% year over year, primarily from ELI-002 manufacturing and clinical-trial costs. Nine-month R&D expense increased 28%.
- Q3 G&A expense increased 198%; the nine-month increase was 119%, reflecting higher personnel and professional costs, including merger and public-company costs.
- Net loss widened year over year, despite other income replacing prior-year other expense. Lower interest expense following conversion of earlier convertible notes was the principal driver of the improvement in other income/expense.
- Operating cash use increased to $22.8 million for the nine months. Financing cash flow of $31.6 million included $24.0 million of cash acquired in the merger and $10.0 million of promissory-note proceeds; merger-related costs and other items reduced the total.
- The merger converted Former Elicio preferred stock into common stock and extinguished promissory-note obligations; the company recorded a $0.6 million gain on extinguishment. A 10:1 reverse stock split preceded the merger.
- The company received a $3.1 million GI Research Foundation grant in September; $1.7 million remained available and was reflected in restricted cash and deferred research obligation at quarter-end.
Outlook, risks and contingencies
Management estimated that existing cash would fund planned operations into the first quarter of 2024, based on its current plan. The filing states that additional capital is needed to fund operations for at least twelve months after issuance of the financial statements and that substantial doubt exists about the company’s ability to continue as a going concern. Management may seek equity or debt financing, licensing, partnerships, collaborations or other strategic transactions, but gives no assurance of success. Failure to obtain funding could require reductions, delays or termination of programs or other operations; equity financing could be highly dilutive.
The company plans to initiate a randomized Phase 2 trial of ELI-002 7P in adjuvant pancreatic cancer patients in early 2024, following support from the study’s independent data monitoring committee. Clinical development, regulatory outcomes, trial timing and enrollment, manufacturing, financing availability and competition remain significant uncertainties. No material legal proceedings were reported. A material weakness in internal control over financial reporting, related to accounting for complex and non-routine transactions, remained unremediated at September 30, 2023; disclosure controls were therefore assessed as ineffective.
Important facts for investors to verify
- Whether the company secured financing after the filing and whether its cash runway and going-concern position changed.
- Progress, timelines and reported results for ELI-002 2P and 7P, including whether the planned Phase 2 trial began.
- Cash burn, accrued obligations and the effect of trial and manufacturing spending on liquidity.
- Remediation of the disclosed material weakness and any subsequent control or reporting issues.
- Merger-related and share-count comparability: 2023 results include Angion only after the merger, and per-share figures reflect the reverse split and merger exchange ratio.